# Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

> **NCT02871297** · PHASE3 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 662 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Vortioxetine

## Key facts

- **NCT ID:** NCT02871297
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-17
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-04-19
- **Target enrollment:** 662 (ACTUAL)
- **Why stopped:** The study was terminated based on new efficacy data from another study.
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871297, "Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02871297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*